Clinical Trial

Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

Study acronym: OVERLORD-MS
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 27, 2025 (before its estimated August 14, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter non-inferiority study, designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-09-30; most recent amendment 2025-06-24.
Status change: Recruiting → Active, Not Recruiting 2023-08-30
Status change: Not Yet Recruiting → Recruiting 2020-11-27
Trial Details
NCT Number NCT04578639
Lead Sponsor Haukeland University Hospital
Collaborators: University Hospital, Akershus, Oslo University Hospital, Helse Stavanger HF, St. Olavs Hospital, University Hospital of North Norway
Conditions Relapsing Remitting Multiple Sclerosis
Enrollment 214 participants
Start Date 2020-11-02
Primary Completion 2025-08-14 (estimated)
Study Completion 2025-09-14 (estimated)
Updated on ClinicalTrials.gov 2025-06-27